CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...
Lineage Cell Therapeutics Inc. (NYSE:LCTX) is one of the best performing penny stocks to buy now. On September 9, HC Wainwright reiterated a ‘Buy’ rating on the stock and a $9 price target, buoyed by ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2025 Earnings Call Transcript August 12, 2025 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations ...
Ratings for Lineage Cell Therapeutics (AMEX:LCTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...
Lineage Cell (LCTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Lineage Cell Therapeutics has found an experienced hearing loss partner to advance a potentially novel transplant for auditory neurons. William Demant Invest, the largest shareholder of Danish hearing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback